A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy

Trial Profile

A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Padsevonil (Primary)
  • Indications Partial epilepsies
  • Focus Proof of concept; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 05 Dec 2017 Primary endpoint has not been met. (75 % responder rate (75 % RR, proportion of subjects who achieve 75 % reduction in focal seizure frequency))
    • 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society
    • 16 Aug 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top